CN102300873A - 针对n-钙黏着蛋白的完全人抗体 - Google Patents

针对n-钙黏着蛋白的完全人抗体 Download PDF

Info

Publication number
CN102300873A
CN102300873A CN2009801544698A CN200980154469A CN102300873A CN 102300873 A CN102300873 A CN 102300873A CN 2009801544698 A CN2009801544698 A CN 2009801544698A CN 200980154469 A CN200980154469 A CN 200980154469A CN 102300873 A CN102300873 A CN 102300873A
Authority
CN
China
Prior art keywords
cancer
cadherin
antibody
cell
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801544698A
Other languages
English (en)
Chinese (zh)
Inventor
R·E·赖特尔
E·莱皮恩
A·M·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN102300873A publication Critical patent/CN102300873A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
CN2009801544698A 2008-11-10 2009-11-10 针对n-钙黏着蛋白的完全人抗体 Pending CN102300873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11304208P 2008-11-10 2008-11-10
US61/113,042 2008-11-10
PCT/US2009/063881 WO2010054377A2 (en) 2008-11-10 2009-11-10 Fully human antibodies against n-cadherin

Publications (1)

Publication Number Publication Date
CN102300873A true CN102300873A (zh) 2011-12-28

Family

ID=42153647

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801544698A Pending CN102300873A (zh) 2008-11-10 2009-11-10 针对n-钙黏着蛋白的完全人抗体

Country Status (13)

Country Link
US (2) US8703920B2 (https=)
EP (1) EP2356145A4 (https=)
JP (1) JP2012508027A (https=)
KR (1) KR20110084309A (https=)
CN (1) CN102300873A (https=)
AU (1) AU2009313239A1 (https=)
BR (1) BRPI0921457A2 (https=)
CA (1) CA2743122A1 (https=)
CO (1) CO6362022A2 (https=)
IL (1) IL212795A0 (https=)
MX (1) MX2011004945A (https=)
RU (1) RU2011123655A (https=)
WO (1) WO2010054377A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2007109347A2 (en) * 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and ly6 e: targets for cancer diagnosis and therapy
JP2011521619A (ja) * 2008-04-04 2011-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍成長、血管新生および転移を妨害する癌標的に対する新規抗体
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
GB201119089D0 (en) 2011-11-04 2011-12-21 Isis Innovation Treatment of musculoskeletal fibroproliferative disorders
EP2830659A1 (en) 2012-03-27 2015-02-04 Novartis AG Treatment of fibrosis
WO2016028663A1 (en) * 2014-08-21 2016-02-25 Johnson Controls Technology Company Battery monitoring system
US20200165351A1 (en) * 2017-06-06 2020-05-28 The Regents Of The University Of California Humanized anti-n-cadherin antibodies and uses thereof
CN117295770A (zh) * 2021-05-13 2023-12-26 上海药明生物技术有限公司 包含抗p-钙粘蛋白抗体的抗体缀合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682901B2 (en) * 1998-05-05 2004-01-27 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889157A (en) * 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6277824B1 (en) * 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
AU2001249064A1 (en) 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
SI1629011T1 (sl) * 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US8663635B2 (en) * 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2007109347A2 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and ly6 e: targets for cancer diagnosis and therapy
JP2011521619A (ja) 2008-04-04 2011-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍成長、血管新生および転移を妨害する癌標的に対する新規抗体
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682901B2 (en) * 1998-05-05 2004-01-27 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, JB，ET AL: "N-cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility", 《JOURNAL OF CELL BIOLOGY》 *
TRAN, NL，ET AL: "N-cadherin expression in human prostate carcinoma cell lines - An epithelial-mesenchymal transformation mediating adhesion with stromal cells", 《AMERICAN JOURNAL OF PATHOLOGY》 *

Also Published As

Publication number Publication date
CO6362022A2 (es) 2012-01-20
US20100233170A1 (en) 2010-09-16
US8703920B2 (en) 2014-04-22
RU2011123655A (ru) 2012-12-20
EP2356145A4 (en) 2012-07-18
JP2012508027A (ja) 2012-04-05
AU2009313239A1 (en) 2011-07-07
US20140017240A1 (en) 2014-01-16
KR20110084309A (ko) 2011-07-21
CA2743122A1 (en) 2010-05-14
WO2010054377A2 (en) 2010-05-14
WO2010054377A3 (en) 2010-09-16
MX2011004945A (es) 2011-11-01
WO2010054377A9 (en) 2011-02-03
EP2356145A2 (en) 2011-08-17
IL212795A0 (en) 2011-07-31
BRPI0921457A2 (pt) 2016-01-12

Similar Documents

Publication Publication Date Title
CN102300873A (zh) 针对n-钙黏着蛋白的完全人抗体
AU2011255870B2 (en) Anti-human TROP-2 antibody having antitumor activity in vivo
JP5219827B2 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
JP2009530645A (ja) Ｎ−カドヘリンおよびｌｙ６−ｅ：癌の診断および治療のための標的
CN104634972A (zh) 抗cxcr1组合物和方法
JP2010508847A (ja) Ｔｅｓ７およびｔｅｓ７に結合する抗体
US9470689B2 (en) N-cadherin: target for cancer diagnosis and therapy
US20150175706A1 (en) Novel Antibodies Against Cancer Target Block Tumor Growth, Angiogenesis and Metastatis
US20100278821A1 (en) N-cadherin: target for cancer diagnosis and therapy
KR101179843B1 (ko) 뉴로필린 ２의 위암 진단 및 치료용 용도
AU2006202023B2 (en) Treatment of metastatic disease
CN102164956A (zh) 通过阻断肿瘤生长、血管发生和转移抵抗癌症的新型抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111228